ArticleCureus2026
Functional Bowel Disorders: A Retrospective Descriptive Study in Dakar, Senegal.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Functional bowel disorders (FBDs) are common pathologies worldwide. However, little is known about the subject in our region. Thus, we undertook a cross-sectional study to address the issue in our population. Methodology We conducted a retrospective descriptive study from January 2016 to December 2022 using data from 2,831 outpatients seen in the hepatogastroenterology department of Idrissa Pouye General Hospital in Dakar. All cases consistent with an FBD according to the Rome IV criteria were included. We collected and analyzed epidemiological, diagnostic, therapeutic, and evolutionary data. Results We included 397 of 2,831 patients (14.02%), with a mean age of 43.23 years and a sex ratio of 0.91. Symptoms were dominated by abdominal pain, which was present in 273 cases (68.8%). The constipation-predominant subtype of irritable bowel syndrome was the most common, found in 273 cases (32.2%). Dyspepsia was the most frequent associated symptom, reported in 102 cases (25.7%). The mean duration of disease at diagnosis was 5.72 years. Anxiety was associated in 11 cases (2.77%), and physical examination findings were normal in 296 cases (74.6%). Additional investigations were performed in 230 patients (57.9%). Treatment was mainly based on antispasmodics, prescribed in 236 cases (59.45%), and defoaming agents, prescribed in 303 cases (76.32%). Clinical evolution was marked by an improvement in symptoms in 183 cases (46%). Conclusions In our cohort, FBD mainly affected young adults, with a female predominance. Abdominal pain was the most common manifestation. Treatment was symptomatic, based on defoaming agents and antispasmodics, and a favorable outcome was observed in nearly half of the patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.